Head And Neck Cancer Drugs Therapeutics Market - Forecast(2024 - 2030)

Head And Neck Cancer Drugs/Therapeutics Market size is estimated to reach $1.8 billion by 2026, growing at a CAGR of 7.3% during the forecast period 2021-2026. The aim of healing for head and neck cancers is to regulate the ailment, but physicians are also interested in caring for the action of the afflicted areas as much as they can and assisting the patient in recovery to usual actions at the earliest following medical care. Head and neck cancer drugs like Erbitux have been planned for application and radiation therapy to heal patients with squamous cell cancer of the head and neck (SCCHN) that cannot be eliminated by surgery. The most recent advancements in surgical procedures and non-surgical therapeutics like immunotherapy and targeted therapy support in caring for the quality of life while providing the most efficient care are driving the growth of the head and neck cancer drugs/therapeutics market during the forecast period 2021-2026. Chemotherapy is a combative kind of chemical drug therapy intended to devastate promptly developing cells in the body. Chemotherapy is normally utilized to heal cancer owing to cancer cells developing and splitting quicker than other cells. Chemotherapy is medical care for head and neck cancer that utilizes strong medications to tear into cancer cells. Radiation Therapy (irradiation or radiotherapy) utilizes high-energy radiation including x-rays which destroy cancer cells. Radiation therapy may be administered externally or internally. However, in the case of head and neck cancers, it is usually administered externally. The availability of enhanced healthcare services owing to government and private company initiatives is set to propel the Head And Neck Cancer Drugs/Therapeutics Market during the forecast period 2021-2026. This represents the Head And Neck Cancer Drugs/Therapeutics Industry Outlook.

Report Coverage

The report "Head And Neck Cancer Drugs/Therapeutics Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Head And Neck Cancer Drugs/Therapeutics Market.

By Product Lines: PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors.
By Application: Chemotherapy, Surgery, Radiation Therapy, Targeted Therapy, Others.
By Distribution Channel: Hospital Pharmacies, Drug Stores, Retail Pharmacies, Online Stores.
By Geography: North America (the U.S, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Rest of South America) and Rest Of The World (Middle East, Africa).

Key Takeaways

• Geographically, North America Head And Neck Cancer Drugs/Therapeutics Market accounted for the highest revenue share in 2020, and it is poised to dominate the market over the period 2021-2026 owing to the increased predominance of HPV (Human Papillomavirus) affected cancers in countries like U.S. and Canada requiring chemotherapy and the soaring rate of smoking in the North American region.
• Head And Neck Cancer Drugs/Therapeutics Market growth is being driven by the rising population of the elderly, unfulfilled medical requirements, and the enormous research financing in oncology. However, the sky-high cost related to healing plan of action like chemotherapy and immunotherapy and the side-effects of ready-to-use healing options is some of the important factors hampering the growth of Head And Neck Cancer Drugs/Therapeutics Market. 
• Detailed Analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Head And Neck Cancer Drugs/Therapeutics Market report.
  
  

  Head And Neck Cancer Drugs/Therapeutics Market Share, by Region, 2020 (%)

  

  For More Details on This Report - Request for Sample

Head And Neck Cancer Drugs/Therapeutics Market Segment Analysis – By Application:

The Head And Neck Cancer Drugs/Therapeutics Market based on the application can be further segmented into Chemotherapy, Surgery, Radiation Therapy, Targeted Therapy, Others. The Chemotherapy Segment held the largest market share in 2020. This growth is owing to the boost in the utilization of chemotherapeutic medications at the time of radiation therapy and the increased advantages of combination therapy. Presently, medications like bleomycin, cetuximab, docetaxel, paclitaxel, capecitabine, hydroxyurea, methotrexate, docetaxel, 5-fluorouracil, and methotrexate are approved for healing of head & neck cancer. Therefore, the increasing predominance of head & neck cancer and increased acceptance of chemotherapeutics for the treatment of head & neck cancer in conjunction with more therapeutics is propelling the market growth of this segment. Targeted therapy is a kind of cancer healing that aims at a particular error (mutation) that assists cancer in developing, partition, and expand. Furthermore, the Targeted Therapy segment is estimated to grow with the fastest CAGR of 7.9% during the forecast period 2021-2026 owing to the increased adoption of molecular targeted therapy with the possibility for a boost in selectivity and lesser unfavorable effects, thus being preferred for healing of Head and neck squamous cell carcinoma (HNSCC)

Head And Neck Cancer Drugs/Therapeutics Market Segment Analysis – By Distribution Channel

The Head And Neck Cancer Drugs/Therapeutics Market based on distribution channels can be further segmented into Hospital Pharmacies, Drug Stores, Retail Pharmacies, Online Stores. The Online Stores Segment held the largest market share in 2020. This growth is owing to ease of availability of necessary medications online at fingertips, just a click away, and the increased inclination towards online stores in comparison with the traditional physical pharmacies especially during the coronavirus pandemic amidst stay-at-home restrictions and global lockdowns. Furthermore, the Online segment is estimated to grow with the fastest CAGR of 7.7% during the forecast period 2021-2026 owing to the boost in the count of internet users and the heightened awareness of online pharmacies. The increasing recognition of online prescriptions, particularly among the elderly and especially abled is further propelling the growth of this segment.

Head And Neck Cancer Drugs/Therapeutics Market Segment Analysis – By Geography

The Head And Neck Cancer Drugs/Therapeutics Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America (Head And Neck Cancer Drugs/Therapeutics Market) held the largest share with 42% of the overall market in 2020. The growth of this region is owing to the increasing count of patients with head and neck cancers, advanced technology, and the soaring high spending on healthcare in the region. Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2021-2026. This growth is owing to factors like the big population base, boost in the occurrences of head and neck cancer cases, and the consequent rise in demand for head and neck cancer integrated therapeutics which is fuelling the progress of the Head And Neck Cancer Drugs/Therapeutics Market in the Asia-Pacific region. The risk determinants like raised alcohol intake, greater cigarette smoking, and tobacco utilization are fuelling the growth of the Head And Neck Cancer Drugs/Therapeutics Market.

Head And Neck Cancer Drugs/Therapeutics Market Drivers

Global Prevalence Of Head And Neck Cancers Is Projected To Drive The Growth Of Head And Neck Cancer Drugs/Therapeutics Market:

As per the Centers For Disease Control and Prevention (CDC), head and neck cancers can occur in the mouth, back of the mouth (pharynx), voice box (larynx), and in the sinuses and nasal cavity. Furthermore, as per CDC, alcohol, and tobacco are important hazard determinants for cancers of the head and neck. According to CDC statistics, nearly 70% of cancers in the oropharynx (including the tonsils, soft palate, and base of the tongue) are connected to human papillomavirus (HPV), a common sexually transmitted virus. Another CDC update indicates that radiation treatments to the head and neck may bring about head and neck cancers. The increasing count of head and neck cancer cases that may be treated using different treatment options like chemotherapy is fuelling the demand for Head And Neck Cancer Drugs/Therapeutics Market during the forecast period 2021-2026.

Immunotherapy For Head And Neck Cancer Is Expected To Boost The Demand Of Head And Neck Cancer Drugs/Therapeutics Market:

Immunotherapy for head and neck cancer offers attractive novel treatment alternatives for patients, particularly those with HPV-associated cancers and without the possibly destructive side-effects of traditional treatments. The most typical head and neck cancer is squamous cell carcinoma of the head and neck (HNSCCA). HNSCCA is responsible for nearly three to five percent of all cancers in the U.S. In 2021, approximately 54,000 people will be diagnosed with head and neck cancer and nearly 11,000 will lose their lives owing to the ailment. If discovered early, head and neck cancer are very curable, frequently with single-modality therapy (surgery or radiation). Immunotherapy is a category of treatments that use a person's immune system to assist in the destruction of cancer cells. There are presently four approved immunotherapy options for head and neck cancer namely Targeted Antibodies - Cetuximab (Erbitux®) and Immunomodulators - Dostarlimab (Jemperli), Immunomodulators - Nivolumab (Opdivo®), Immunomodulators - Pembrolizumab (Keytruda®). These exciting immunotherapy options are driving the growth of the Head And Neck Cancer Drugs/Therapeutics Market during the forecast period 2021 -2026.

Head And Neck Cancer Drugs/Therapeutics Market Challenges

Side-Effects Of Head And Neck Cancer Surgery Can Hamper The Growth Of The Market

Typical side-effects from Head and neck surgery includes temporary or permanent loss of normal voice, faulty speech, and hearing loss. Patients frequently find it hard to chew or swallow after cancer surgery, which can need a tube injected into the stomach for feeding. This issue is hampering the growth of the Head And Neck Cancer Drugs/Therapeutics Market.

Head And Neck Cancer Drugs/Therapeutics Market Landscape:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Head And Neck Cancer Drugs/Therapeutics Market. Key companies of this market include:

1. AB Science SA
2. AbbVie Inc.
3. Acceleron Pharma, Inc.
4. Astellas Pharma Inc.
5. AstraZeneca Plc.
6. Bayer AG
7. Boston Biomedical, Inc.
8. Bristol-Myers Squibb Company
9. GE Healthcare
10. Siemens Healthcare

Acquisitions/Product Launches:

• In September 2021, AB Science declared that a novel clinical trial with masitinib in symptomatic mild and moderate COVID-19 had been approved by the Regulatory Authorities of Russia and South Africa. Masitinib is being matured as a novel SARS-CoV-2 protease inhibitor antiviral therapy, with two phases of studies in the complementary populations of non-hospitalized (non-severe) and hospitalized (severe) COVID-19 patients.
• In April 2021, Allergen Aesthetics, an AbbVie company, declared the kick-off of SkinMedica®. Neck Correct Cream, the earliest product from the professional-grade skin care line formulated to focus on the particular biology of the skin on the neck and decollete area. SkinMedica® Neck Correct Cream was planned to avert the initial signs and also treat the discernible countenance of moderate to severe neck aging.

Related Reports

Head & Neck Cancer Drugs Market - Forecast(2021 - 2026)
Report Code: HCR 94267

Oncology Drugs Market - Forecast(2021 - 2026)
Report Code: HCR 1186

For more Lifesciences and Healthcare related reports, please click here